Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Palvella Therapeutics, Inc. has received a consensus recommendation of "Buy" from eleven research firms, with an average one-year price target of $58.50.
• Recent price target upgrades include Chardan Capital raising its target from $50.00 to $60.00 and HC Wainwright increasing its target from $38.00 to $75.00.
• In the latest quarter, Palvella reported an EPS of ($0.86), missing the consensus estimate of ($0.78).

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) have earned a consensus recommendation of "Buy" from the eleven research firms that are presently covering the stock, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $58.50.

PVLA has been the subject of several recent research reports. Chardan Capital boosted their price target on shares of Palvella Therapeutics from $50.00 to $60.00 and gave the company a "buy" rating in a report on Friday, August 15th. HC Wainwright boosted their price objective on shares of Palvella Therapeutics from $38.00 to $75.00 and gave the stock a "buy" rating in a research note on Friday, August 15th. Lifesci Capital initiated coverage on shares of Palvella Therapeutics in a research note on Monday, August 4th. They set an "outperform" rating and a $90.00 price objective for the company. Truist Financial initiated coverage on shares of Palvella Therapeutics in a research note on Monday, July 21st. They set a "buy" rating and a $56.00 price objective for the company. Finally, Raymond James Financial set a $54.00 price objective on shares of Palvella Therapeutics and gave the stock an "outperform" rating in a research note on Tuesday, August 5th.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $51.31 on Friday. Palvella Therapeutics has a one year low of $11.17 and a one year high of $52.87. The firm has a market cap of $567.49 million, a P/E ratio of -4.24 and a beta of -0.01. The firm has a 50-day simple moving average of $32.41 and a 200-day simple moving average of $26.34.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.08). On average, research analysts predict that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $37,000. Spire Wealth Management bought a new position in shares of Palvella Therapeutics during the 1st quarter worth approximately $70,000. JPMorgan Chase & Co. grew its position in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock worth $73,000 after purchasing an additional 3,242 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Palvella Therapeutics during the 2nd quarter worth approximately $85,000. Finally, BNP Paribas Financial Markets purchased a new stake in Palvella Therapeutics during the 2nd quarter worth approximately $104,000. Institutional investors own 40.11% of the company's stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.